Alan Nadour, MD
Cardiovascular Disease · Cary, NCNPI 1326178302
Payments from drug & device makers
Across 37 payments — averaging $226.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$8K
- Bard Peripheral Vascular, Inc.$243
- Novo Nordisk$197
- BD$136
- Lilly USA, LLC$66
- Nevro Corp.$53
- plus $182 from 9 others
What the payments were for
- Food & beverage$87710%
- Other$7,50090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $7,500 |
| Bard Peripheral Vascular, Inc. | 7 | $243 |
| Novo Nordisk | 11 | $197 |
| BD | 1 | $136 |
| Lilly USA, LLC | 4 | $66 |
| Nevro Corp. | 3 | $53 |
| Organogenesis Inc. | 2 | $47 |
| Boehringer Ingelheim | 1 | $21 |
| Novartis | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Almirall LLC | 1 | $15 |
| Dermira, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,377 in reported general payments places this provider in the 65th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $11,598 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 12 | $876 |
| Metoprolol Succinate | 15 | $450 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 34 | $361 |
| Atorvastatin Calcium | 36 | $310 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 20 | $300 |
| Omeprazole | 24 | $175 |
| Doxazosin Mesylate | 14 | $157 |
| Rosuvastatin Calcium | 15 | $112 |
| Amlodipine Besylate | 18 | $111 |
| Lovastatin | 12 | $108 |
| Losartan Potassium | 13 | $74 |
| Escitalopram Oxalate | 14 | $71 |
| Lisinopril | 19 | $70 |
| Simvastatin | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cary
- Priyavadan ShahCary$871K
- Pratik DesaiCary$777K
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Michael ShapiroWinston-Salem$5.4M
- Kirkwood AdamsChapel Hill$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.